Abstract
Microbes, which live in the human body, affect a large set of pathophysiological processes. Changes in the composition and proportion of the microbiome are associated with metabolic diseases (Fulbright et al., PLoS Pathog 13:e1006480, 2017; Maruvada et al., Cell Host Microbe 22:589–599, 2017), psychiatric disorders (Macfabe, Glob Adv Health Med 2:52–66, 2013; Kundu et al., Cell 171:1481–1493, 2017), and neoplastic diseases (Plottel and Blaser, Cell Host Microbe 10:324–335, 2011; Schwabe and Jobin, Nat Rev Cancer 13:800–812, 2013; Zitvogel et al., Cell 165:276–287, 2016). However, the number of directly tumorigenic bacteria is extremely low. Microbial dysbiosis is connected to cancers of the urinary tract (Yu, Arch Med Sci 11:385–394, 2015), cervix (Chase, Gynecol Oncol 138:190–200, 2015), skin (Yu et al., J Drugs Dermatol 14:461–465, 2015), airways (Gui et al., Genet Mol Res 14:5642–5651, 2015), colon (Garrett, Science 348:80–86, 2015), lymphomas (Yamamoto and Schiestl, Int J Environ Res Public Health 11:9038–9049, 2014; Yamamoto and Schiestl, Cancer J 20:190–194, 2014), prostate (Yu, Arch Med Sci 11:385–394, 2015), and breast (Flores et al., J Transl Med 10:253, 2012; Fuhrman et al., J Clin Endocrinol Metab 99:4632–4640, 2014; Xuan et al., PLoS One 9:e83744, 2014; Goedert et al., J Natl Cancer Inst 107:djv147, 2015; Chan et al., Sci Rep 6:28061, 2016; Hieken et al., Sci Rep 6:30751, 2016; Urbaniak et al., Appl Environ Microbiol 82:5039–5048, 2016; Goedert et al., Br J Cancer 118:471–479, 2018). Microbial dysbiosis can influence organs in direct contact with the microbiome and organs that are located at distant sites of the body. The altered microbiota can lead to a disruption of the mucosal barrier (Plottel and Blaser, Cell Host Microbe 10:324–335, 2011), promote or inhibit tumorigenesis through the modification of immune responses (Kawai and Akira, Int Immunol 21:317–337, 2009; Dapito et al., Cancer Cell 21:504–516, 2012) and microbiome-derived metabolites, such as estrogens (Flores et al., J Transl Med 10:253, 2012; Fuhrman et al., J Clin Endocrinol Metab 99:4632–4640, 2014), secondary bile acids (Rowland, Role of the gut flora in toxicity and cancer, Academic Press, London, p x, 517 p., 1988; Yoshimoto et al., Nature 499:97–101, 2013; Xie et al., Int J Cancer 139:1764–1775, 2016; Shellman et al., Clin Otolaryngol 42:969–973, 2017; Luu et al., Cell Oncol (Dordr) 41:13–24, 2018; Miko et al., Biochim Biophys Acta Bioenerg 1859:958–974, 2018), short-chain fatty acids (Bindels et al., Br J Cancer 107:1337–1344, 2012), lipopolysaccharides (Dapito et al., Cancer Cell 21:504–516, 2012), and genotoxins (Fulbright et al., PLoS Pathog 13:e1006480, 2017). Thus, altered gut microbiota may change the efficacy of chemotherapy and radiation therapy (McCarron et al., Br J Biomed Sci 69:14–17, 2012; Viaud et al., Science 342:971–976, 2013; Montassier et al., Aliment Pharmacol Ther 42:515–528, 2015; Buchta Rosean et al., Adv Cancer Res 143:255–294, 2019). Taken together, microbial dysbiosis has intricate connections with neoplastic diseases; hereby, we aim to highlight the major contact routes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Fulbright LE, Ellermann M, Arthur JC (2017) The microbiome and the hallmarks of cancer. PLoS Pathog 13(9):e1006480
Maruvada P et al (2017) The human microbiome and obesity: moving beyond associations. Cell Host Microbe 22(5):589–599
Macfabe D (2013) Autism: metabolism, mitochondria, and the microbiome. Glob Adv Health Med 2(6):52–66
Kundu P et al (2017) Our gut microbiome: the evolving inner self. Cell 171(7):1481–1493
Plottel CS, Blaser MJ (2011) Microbiome and malignancy. Cell Host Microbe 10(4):324–335
Schwabe RF, Jobin C (2013) The microbiome and cancer. Nat Rev Cancer 13(11):800–812
Zitvogel L et al (2016) Microbiome and anticancer immunosurveillance. Cell 165(2):276–287
Yu H et al (2015) Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia. Arch Med Sci 11(2):385–394
Chase D et al (2015) The vaginal and gastrointestinal microbiomes in gynecologic cancers: a review of applications in etiology, symptoms and treatment. Gynecol Oncol 138(1):190–200
Yu Y et al (2015) The role of the cutaneous microbiome in skin cancer: lessons learned from the gut. J Drugs Dermatol 14(5):461–465
Gui QF et al (2015) Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. Genet Mol Res 14(2):5642–5651
Garrett WS (2015) Cancer and the microbiota. Science 348(6230):80–86
Yamamoto ML, Schiestl RH (2014) Lymphoma caused by intestinal microbiota. Int J Environ Res Public Health 11(9):9038–9049
Yamamoto ML, Schiestl RH (2014) Intestinal microbiome and lymphoma development. Cancer J 20(3):190–194
Flores R et al (2012) Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. J Transl Med 10:253
Fuhrman BJ et al (2014) Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin Endocrinol Metab 99(12):4632–4640
Xuan C et al (2014) Microbial dysbiosis is associated with human breast cancer. PLoS One 9(1):e83744
Goedert JJ et al (2015) Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst 107(8):djv147
Chan AA et al (2016) Characterization of the microbiome of nipple aspirate fluid of breast cancer survivors. Sci Rep 6:28061
Hieken TJ et al (2016) The microbiome of aseptically collected human breast tissue in benign and malignant disease. Sci Rep 6:30751
Urbaniak C et al (2016) The microbiota of breast tissue and its association with breast cancer. Appl Environ Microbiol 82(16):5039–5048
Goedert JJ et al (2018) Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota. Br J Cancer 118(4):471–479
Kawai T, Akira S (2009) The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 21(4):317–337
Dapito DH et al (2012) Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21(4):504–516
Rowland IR (1988) Role of the gut flora in toxicity and cancer. Academic Press, London, p x, 517 p
Yoshimoto S et al (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499(7456):97–101
Xie G et al (2016) Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer 139(8):1764–1775
Shellman Z et al (2017) Bile acids: a potential role in the pathogenesis of pharyngeal malignancy. Clin Otolaryngol 42(5):969–973
Luu TH et al (2018) Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells. Cell Oncol (Dordr) 41(1):13–24
Miko E et al (2018) Lithocholic acid, a bacterial metabolite reduces breast cancer cell proliferation and aggressiveness. Biochim Biophys Acta Bioenerg 1859(9):958–974
Bindels LB et al (2012) Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br J Cancer 107(8):1337–1344
McCarron AJ et al (2012) Antibacterial effects on acinetobacter species of commonly employed antineoplastic agents used in the treatment of haematological malignancies: an in vitro laboratory evaluation. Br J Biomed Sci 69(1):14–17
Viaud S et al (2013) The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342(6161):971–976
Montassier E et al (2015) Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther 42(5):515–528
Buchta Rosean C et al (2019) Impact of the microbiome on cancer progression and response to anti-cancer therapies. Adv Cancer Res 143:255–294
Garcia-Castillo V et al (2016) Microbiota dysbiosis: a new piece in the understanding of the carcinogenesis puzzle. J Med Microbiol 65(12):1347–1362
Arslan N (2014) Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol 20(44):16452–16463
Lynch SV, Pedersen O (2016) The human intestinal microbiome in health and disease. N Engl J Med 375(24):2369–2379
Khan AA, Shrivastava A, Khurshid M (2012) Normal to cancer microbiome transformation and its implication in cancer diagnosis. Biochim Biophys Acta 1826(2):331–337
Walsh CJ et al (2014) Beneficial modulation of the gut microbiota. FEBS Lett 588(22):4120–4130
Petersen C, Round JL (2014) Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol 16(7):1024–1033
Kovacs T et al (2019) Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptors. Sci Rep 9(1):1300
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Balkwill FR, Capasso M, Hagemann T (2012) The tumor microenvironment at a glance. J Cell Sci 125(23):5591–5596
Fernandez MF et al (2018) Breast cancer and its relationship with the microbiota. Int J Environ Res Public Health 15(8):E1747
Hackam DJ, Good M, Sodhi CP (2013) Mechanisms of gut barrier failure in the pathogenesis of necrotizing enterocolitis: toll-like receptors throw the switch. Semin Pediatr Surg 22(2):76–82
Brahmer JR et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465
Yang JC et al (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30(8):825–830
Topalian SL et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454
Vetizou M et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350(6264):1079–1084
Sivan A et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264):1084–1089
Gopalakrishnan V et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97–103
Matson V et al (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359(6371):104–108
Routy B et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371):91–97
Ridlon JM, Kang DJ, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47(2):241–259
Louis P, Hold GL, Flint HJ (2014) The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 12(10):661–672
Miko E et al (2019) Microbiome-microbial metabolome-cancer cell interactions in breast cancer-familiar, but unexplored. Cell 8(4):E293
Gandhi N, Das GM (2019) Metabolic reprogramming in breast cancer and its therapeutic implications. Cell 8(2):E89
Sansone P et al (2017) Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. Proc Natl Acad Sci U S A 114(43):E9066–E9075
Ivan J et al (2017) The short-chain fatty acid propionate inhibits adipogenic differentiation of human chorion-derived mesenchymal stem cells through the free fatty acid receptor 2. Stem Cells Dev 26(23):1724–1733
Fruge AD et al (2018) Fecal Akkermansia muciniphila is associated with body composition and microbiota diversity in overweight and obese women with breast Cancer participating in a presurgical weight loss trial. J Acad Nutr Diet. https://doi.org/10.1016/j.jand.2018.08.164
Swales KE et al (2006) The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res 66(20):10120–10126
Salaspuro M (1997) Microbial metabolism of ethanol and acetaldehyde and clinical consequences. Addict Biol 2(1):35–46
Vida A et al (2018) Deletion of poly(ADPribose) polymerase-1 changes the composition of the microbiome in the gut. Mol Med Rep 18(5):4335–4341
Morgan XC et al (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13(9):R79
Giles GI, Jacob C (2002) Reactive sulfur species: an emerging concept in oxidative stress. Biol Chem 383(3–4):375–388
Khoruts A et al (2010) Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44(5):354–360
Roh YS, Seki E (2013) Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol 28(Suppl 1):38–42
Zambirinis CP et al (2014) Pancreatic cancer, inflammation, and microbiome. Cancer J 20(3):195–202
Houghton AM (2013) Mechanistic links between COPD and lung cancer. Nat Rev Cancer 13(4):233–245
Schmidt BL et al (2014) Changes in abundance of oral microbiota associated with oral cancer. PLoS One 9(6):e98741
Zackular JP et al (2013) The gut microbiome modulates colon tumorigenesis. MBio 4(6):e00692–e00613
Arthur JC, Jobin C (2011) The struggle within: microbial influences on colorectal cancer. Inflamm Bowel Dis 17(1):396–409
Banerjee S et al (2015) Distinct microbiological signatures associated with triple negative breast cancer. Sci Rep 5:15162
Luu TH et al (2017) Intestinal proportion of Blautia sp. is associated with clinical stage and histoprognostic grade in patients with early-stage breast cancer. Nutr Cancer 69(2):267–275
Acknowledgments
Our work is supported by grants from NKFIH (K123975, PD124110, FK128387, GINOP-2.3.2-15-2016-00006) and the Hungarian Academy of Sciences (NKM-26/2019). EM is supported by a Bolyai Fellowship from the Hungarian Academy of Sciences. We are grateful to Dr. Karen Uray (Department of Medical Chemistry, University of Debrecen) for the revision of the text.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kovács, T., Mikó, E., Ujlaki, G., Sári, Z., Bai, P. (2020). The Microbiome as a Component of the Tumor Microenvironment. In: Birbrair, A. (eds) Tumor Microenvironment. Advances in Experimental Medicine and Biology, vol 1225. Springer, Cham. https://doi.org/10.1007/978-3-030-35727-6_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-35727-6_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-35726-9
Online ISBN: 978-3-030-35727-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)